|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with aggressive tumor factors, including lymph node metastasis (P=0.001) and advanced disease stage (P=0.009).
|
31602213 |
2019 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
<b>Objective:</b> The COMBI-AD trial demonstrated the efficacy and safety of dabrafenib and trametinib in combination vs placebo as adjuvant treatment of patients with BRAF V600E/K mutation-positive resected Stage IIIA (lymph node metastasis >1 mm), IIIB, or IIIC melanoma.
|
31223037 |
2019 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We detected a BRAF V600E mutation by Sanger sequencing in the second primary and distant lymph node metastases, but not in the first primary or sentinel lymph node.
|
30222690 |
2019 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
One case not meeting criteria for NIFTP maintained the diagnosis of encapsulated FVPTC without invasion but demonstrated significant mitotic activity (three mitoses/ten HPF) and lacked lymph node metastases and BRAF V600E mutation.
|
29368294 |
2018 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We present a case of a woman with BRAF V600E-mutated malignant melanoma and rapidly progressing liver, bone, and lymph node metastases.
|
29215399 |
2018 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression of BRAF V600E, RET/PTC, and concomitant expression of BRAF V600E and RET/PTC were significantly associated with patient age and lymph node metastasis (P<0.05).
|
30254191 |
2018 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
EphB3 expression was negatively associated with invasive depth (P = 0.016, r<sub>s</sub> = -0.213), lymph node metastasis (P = 0.000, r<sub>s</sub> = -0.490), and TNM stage (P = 0.000, r<sub>s</sub> = -0.390), and was positively associated with poor differentiation (P = 0.001, r<sub>s</sub> = 0.290), BRAF V600E mutation (P = 0.008, r<sub>s</sub> = 0.235), and longer overall survival (P < 0.001).
|
30535864 |
2018 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our study showed that there was no significant association of BRAF V600E mutation with the gender, age, tumor size and lymph node metastasis in PTCs.
|
29254799 |
2018 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Increased EHD2 mRNA expression level was associated with extrathyroidal extension (p < 0.001), pT3-4 (p < 0.001), lymph node metastasis (p < 0.001), higher risk of recurrence (p < 0.001), and BRAF V600E (p < 0.001).
|
28358874 |
2017 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared with wild-type BRAF, the BRAF(V600E) mutation was associated with aggressive clinicopathological factors, including extrathyroidal extension, higher TNM stage, lymph node metastasis, and recurrence, and was associated with reduced overall survival; however, there was no significant association between the presence of BRAF mutation and distant metastasis.
|
27600854 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF c.1799T>A (p.Val600Glu) substitution was present in 59.0% Chinese PTCs, more frequently observed in patients with lymph node metastasis (P = 1.6 × 10(-4)).
|
26941397 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) in PTC predicts an increased risk of lymph node metastasis, extra-thyroidal extension and reduced disease-free survival.
|
27138882 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
By contrast, positive status of BRAF(V600E) mutation was a significant predictor of multifocality (OR = 1.23; 95%CI = 1.14-1.32), extrathyroidal extension (OR = 2.23; 95%CI = 1.90-2.63), TNM stage (OR = 1.67; 95%CI = 1.53-1.81), lymph node metastasis (OR = 1.67; 95%CI = 1.45-1.93), vascular invasion (OR = 1.47; 95%CI = 1.22-1.79) and recurrence/persistence (OR = 2.33; 95%CI = 1.71-3.18).
|
26871894 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no significant correlation with BRAF (V600E) mutation and age, gender, tumor size, ETE, central lymph node metastasis, the status of pT, pN1a-b, and distant metastasis.
|
26951110 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We report a 65-year-old woman with anaplastic thyroid carcinoma (BRAF V600E mutation) who had lymph node metastases (pT4 N1b) treated by total thyroidectomy, postoperative radiotherapy, adjuvant chemotherapy (paclitaxel and pazopanib) and targeted therapy (vemurafenib).
|
26347145 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
|
26950846 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Extrathyroidal invasion, surgical margin positivity, and lymph node metastasis were compared with BRAF(V600E) mutation and NIS expression.
|
27180062 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Lymph node metastasis and BRAF V600E mutations were more frequent in papillary thyroid cancers with high LOC100507661 expression.
|
27151833 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Significant correlation was observed between the expression of 2 lncRNAs (XLOC_051122 and XLOC_006074) and 1) lymph node metastasis (N stage) and 2) BRAF(V600E) mutation.
|
27459529 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
|
26268700 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found significant association between BRAF (V600E) mutation and age (P < 0.0001), extrathyroidal invasion (P = 0.017), lymph node metastasis (P = 0.038) and TNM stage III/IV (P = 0.001).
|
27387551 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, Hashimoto's thyroiditis was related to less lymph node metastasis and extrathyroidal extension in PTCs with BRAF(V6</span>00E) mutation.
|
26041461 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation, BRAF V600E IHC, low ΔCt, and high BRAF RNA ISH were significantly associated with lymph node metastasis.
|
25468810 |
2015 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation status was not associated with clinicopathologic characteristics of aggressive behavior such as extrathyroidal extension, lymph node metastases, higher T-categories, male sex, and greater age.
|
25482468 |
2015 |